Table 1 Baseline demographics and disease characteristics
|  | RAM + DOC (n = 263) | PL + DOC (n = 267) |
|---|---|---|
Median age, years (range) | 65 (34–86) | 66 (32–83) |
Male | 213 (81) | 215 (81) |
Race | Â | Â |
White | 203 (77) | 204 (76) |
Asian | 54 (20) | 61 (23) |
ECOG performance status | Â | Â |
0 | 121 (46) | 125 (47) |
1 | 139 (53) | 142 (53) |
Geography | Â | Â |
North America | 24 (9) | 24 (9) |
East Asia | 53 (20) | 57 (21) |
Europe/Other | 186 (71) | 186 (70) |
Primary tumor site | Â | Â |
Bladder | 180 (68) | 177 (66) |
Urethra | 7 (3) | 6 (2) |
Renal pelvis | 39 (15) | 42 (16) |
Ureter | 33 (13) | 37 (14) |
Other | 1 (< 1) | 5 (2) |
Sites of metastases | Â | Â |
Lymph node only | 41 (16) | 42 (16) |
Visceral | 182 (69) | 188 (70) |
Liver | 78 (30) | 69 (26) |
Lung | 98 (37) | 121(45) |
Bone | 56 (21) | 53 (20) |
Hemoglobin < 10 g/dL | 34 (13) | 36 (13) |
Patients with time since previous chemotherapy < 3mo | 115 (44) | 126 (47) |
Bellmunt risk factors | Â | Â |
0 | 88 (33) | 93 (35) |
1 | 105 (40) | 109 (41) |
2 | 64 (24) | 57 (21) |
3 | 6 (2) | 8 (3) |
Prior neoadjuvant or adjuvant therapy | 87 (33) | 107 (40) |
Prior platinum-based therapy: | Â | Â |
Cisplatin | 161 (61) | 189 (71) |
Carboplatin | 97 (37) | 77 (29) |
Prior immune checkpoint inhibitor | 17 (7) | 28 (10) |